Day: September 30, 2024

SOMERSET, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, today announced a strategic partnership with ChartSwap, a leading provider of business-to-business (B2B) medical and billing records exchange, to launch “CareCloud Powered by ChartSwap.” This new collaboration will significantly enhance the way medical records are handled and accessed, enabling CareCloud’s providers to focus more on delivering high-quality patient care. Through this partnership, ChartSwap will serve as the dedicated portal for handling Release of Information (ROI) requests for medical information at CareCloud provider locations. Requestors, including law firms and insurance companies, will now be able...

RUTLAND, Vt., Sept. 30, 2024 (GLOBE NEWSWIRE) — Casella Waste Systems, Inc. (Nasdaq: CWST), a regional solid waste, recycling, and resource management services company, today announced that it has entered into a $1.5 billion amended and restated credit agreement with Bank of America, N.A. as administrative agent and lender and a syndicate of other lenders (the “Credit Facility”). The Credit Facility matures on September 27, 2029 and replaces the Company’s prior $1.08 billion credit facility. The Credit Facility provides for an $800 million term loan A facility and a $700 million revolving credit facility, with a $155 million sublimit for letters of credit. The revolving credit facility was undrawn at closing and provides increased liquidity for general corporate purposes, including the execution of the Company’s acquisition strategy....

Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced the publication of full results from two pivotal Phase 3 clinical trials (MIRA-2 and MIRA-3) that evaluated the safety and efficacy of RYZUMVI™ (Phentolamine Ophthalmic Solution 0.75%) for the treatment of pharmacologically-induced mydriasis in the peer-reviewed journal Ophthalmology. The results demonstrated that Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1...

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024. Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company’s first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder caused by single nucleotide variants (SNVs) in the SERPINA1 gene. Oral Presentation Information:Title: KRRO-110, an RNA Editing Oligonucleotide For The Treatment...

Appointments Expand Executive Team to Drive Operational ExcellenceKirsten MoenKirsten MoenPORTLAND, Tenn., Sept. 30, 2024 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals”), a global leader in electrical balance of system (“EBOS”) solutions for the energy transition market, announced today that it has further strengthened its executive team with two new additions to drive operational excellence. Kirsten Moen, newly appointed Chief Operations Officer, is an accomplished operations and manufacturing executive with extensive experience in leading organizations such as Eaton and Stanley Black & Decker. Her established track record of driving lean manufacturing, optimizing manufacturing processes, and delivering measurable results will further position Shoals as a leader in the renewable energy industry. “It...

MORRISVILLE, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston. Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: “Every year, CHEST unites the next generation of medical professionals and organizations responsible for advancing patient care and educating the future leaders in our field. As such, we are proud to be sharing insight regarding our ongoing ASCENT trial evaluating the safety and tolerability of YUTREPIA™ (treprostinil) inhalation powder in patients with pulmonary hypertension...

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October:H.C. Wainwright 8th Annual MASH Virtual ConferenceFireside Chat at 3:00pm ET/12:00pm PT on October 7, 2024H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceFireside Chat at 3:00pm ET/12:00pm PT on October 8, 2024A live webcast of each event will be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcasts will be available following the presentation for at least...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced an upcoming poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, which will be held in Philadelphia, October 25–30, 2024. Biora’s submission was awarded a Presidential Poster Award by the ACG Abstract Selection Committee. Each year less than 5% of accepted abstracts receive this distinction for high quality, novel, unique, and interesting research. Details of the presentation are as follows:Poster Number: P4275   Session Date: October 29, 2024 10:30 AM – 4:00 PM ET   Presenting Author: Brian Feagan, MD, FRCPC​​   All research presented at ACG 2024, including abstract titles, is strictly embargoed until Sunday,...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the efficacy and safety of petosemtamab, a Biclonics® targeting EGFR and LGR5, in combination with pembrolizumab, compared to pembrolizumab as first line (1L) therapy for patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC), referred to as the LiGeR-HN1 trial. Merus has confirmed through feedback with the U.S. Food and Drug Administration (FDA) that petosemtamab 1500 mg every two weeks is appropriate for further development in HNSCC as...

Initial Order Marks First Income Milestone for Company as it Secures Initial Revenue Stream for Alternative Protein Premixes Rehovot, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) — Steakholder Foods Ltd. (Nasdaq: STKH) (the “Company”), a leading innovator in alternative proteins production and 3D printing production technologies, today announced that it has received an initial purchase order, since it was incorporated, from Bondor Foods Ltd. under the commercial agreement signed earlier this month. The order represents a significant milestone for Steakholder Foods as it marks the Company’s first revenue for its proprietary alternative protein premixes in 2024. The purchase order follows the recently announced commercial agreement between Steakholder Foods and Bondor Foods, a renowned frozen foods manufacturer and institutional market...